Skip to content

Tempest Therapeutics, Inc.

TPST

CIK 0001544227

← back to feed
Revenue (TTM)
$276K
Q1 May 2026
Net Income (TTM)
−$49.94M
+37.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$8.55
+67.5% YoY Q1 May 2026
Gross Margin
13.4%
Q1 May 2026
Operating Margin
-18,194.9%
Q1 May 2026
Net Margin
-18,093.1%
Q1 May 2026
Free Cash Flow (TTM)
−$31.34M
Q1 May 2026
Cash
$1.81M
Q1 May 2026
Total Debt
$199K
Q1 May 2026
Shares Outstanding
14.81M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings